KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Work In Process (2021 - 2025)

Bionano Genomics' Work In Process history spans 5 years, with the latest figure at $388000.0 for Q3 2025.

  • For Q3 2025, Work In Process fell 89.17% year-over-year to $388000.0; the TTM value through Sep 2025 reached $388000.0, down 89.17%, while the annual FY2024 figure was $2.3 million, 76.01% down from the prior year.
  • Work In Process for Q3 2025 was $388000.0 at Bionano Genomics, down from $653000.0 in the prior quarter.
  • Across five years, Work In Process topped out at $10.6 million in Q2 2023 and bottomed at $388000.0 in Q3 2025.
  • The 5-year median for Work In Process is $5.8 million (2022), against an average of $5.6 million.
  • The largest annual shift saw Work In Process soared 325.0% in 2022 before it plummeted 89.17% in 2025.
  • A 5-year view of Work In Process shows it stood at $1.7 million in 2021, then skyrocketed by 325.0% to $7.1 million in 2022, then surged by 38.77% to $9.8 million in 2023, then plummeted by 76.01% to $2.3 million in 2024, then tumbled by 83.48% to $388000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Work In Process are $388000.0 (Q3 2025), $653000.0 (Q2 2025), and $1.6 million (Q1 2025).